Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,963 shares of the life sciences company’s stock after selling 666 shares during the period. Washington Trust Advisors Inc.’s holdings in Illumina were worth $663,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bleakley Financial Group LLC acquired a new position in shares of Illumina during the 4th quarter worth $751,000. Zacks Investment Management purchased a new stake in Illumina during the 3rd quarter worth about $2,924,000. Van ECK Associates Corp increased its position in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after purchasing an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC purchased a new stake in Illumina during the 4th quarter worth about $1,464,000. Finally, Allworth Financial LP increased its position in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after purchasing an additional 6,263 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ILMN. Royal Bank of Canada dropped their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Piper Sandler lifted their price objective on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Stephens lifted their price objective on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Robert W. Baird dropped their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Canaccord Genuity Group lowered their price target on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Stock Performance

Illumina stock opened at $85.69 on Thursday. The stock’s 50 day moving average price is $120.36 and its 200 day moving average price is $132.17. The firm has a market capitalization of $13.57 billion, a PE ratio of -11.16, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.